이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Aceso Life Science Group 과거 수익 실적

과거 기준 확인 0/6

Aceso Life Science Group의 수입은 연평균 -6.9%의 비율로 감소해 온 반면, Consumer Finance 산업은 수입이 연평균 1.5%의 비율로 감소했습니다. 매출은 연평균 16.4%의 비율로 증가해 왔습니다.

주요 정보

-6.9%

수익 성장률

0.9%

EPS 성장률

Consumer Finance 산업 성장	-2.1%
매출 성장률	16.4%
자기자본 수익률	-44.6%
순이익	-3,553.8%
최근 수익 업데이트	31 Mar 2024

최근 과거 실적 업데이트

Recent updates

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Feb 23

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Jan 01

수익 및 비용 분석

Aceso Life Science Group 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:474 수익, 비용 및 수입 (HKD Millions )
날짜	수익	수익	G+A 비용
31 Mar 24	13	-462	124
31 Dec 23	132	-441	124
30 Sep 23	198	-420	123
30 Jun 23	203	-342	125
31 Mar 23	207	-264	126
31 Dec 22	135	-301	134
30 Sep 22	115	-338	141
30 Jun 22	143	-354	147
31 Mar 22	170	-370	153
31 Dec 21	8	-197	162
30 Sep 21	-154	-25	171
30 Jun 21	-141	-200	188
31 Mar 21	-129	-376	204
31 Dec 20	-43	-523	209
30 Sep 20	43	-671	213
30 Jun 20	9	-477	201
31 Mar 20	-25	-284	189
31 Dec 19	48	-162	196
30 Sep 19	120	-40	203
30 Jun 19	148	-211	211
31 Mar 19	175	-381	219
31 Dec 18	200	-533	223
30 Sep 18	224	-686	226
30 Jun 18	237	-565	226
31 Mar 18	250	-445	227
31 Dec 17	235	-1,209	205
30 Sep 17	220	-1,972	183
30 Jun 17	169	-2,526	158
31 Mar 17	118	-3,079	133
31 Dec 16	95	-1,911	119
30 Sep 16	71	-743	106
30 Jun 16	57	-109	97
31 Mar 16	42	524	89
31 Dec 15	20	498	80
30 Sep 15	-1	471	70
30 Jun 15	-3	997	73
31 Mar 15	-5	1,523	75
31 Dec 14	6	1,281	79
30 Sep 14	17	1,039	82
30 Jun 14	22	466	80
31 Mar 14	26	-107	78
31 Dec 13	-13	-122	67
30 Sep 13	-52	-137	56

양질의 수익: 474 은(는) 현재 수익성이 없습니다.

이익 마진 증가: 474 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 474 은(는) 수익성이 없으며 지난 5년 동안 연간 6.9% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 474 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: 474 은(는) 수익성이 없어 지난 해 수익 성장을 Consumer Finance 업계( 6.8% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: 474 현재 수익성이 없기 때문에 마이너스 자본 수익률( -20.33% )을 갖습니다.

Aceso Life Science Group 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

Recent updates

New major risk - Revenue and earnings growth

Aceso Life Science Group Limited to Report Fiscal Year 2024 Final Results on Jun 26, 2024

Aceso Life Science Group Limited Announces Resignation of Xu Haiying as Executive Director

First half 2024 earnings released: HK$0.028 loss per share (vs HK$0.007 loss in 1H 2023)

New major risk - Revenue size

Aceso Life Science Group Limited Provides Group Earnings Guidance for the Six Months Ended 30 September 2023

Aceso Life Science Group Limited to Report First Half, 2024 Results on Nov 28, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited, Annual General Meeting, Sep 15, 2023

Full year 2023 earnings released: HK$0.036 loss per share (vs HK$0.051 loss in FY 2022)

Aceso Life Science Group Limited to Report Fiscal Year 2023 Results on Jun 28, 2023

New minor risk - Market cap size

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

First half 2023 earnings released: HK$0.007 loss per share (vs HK$0.012 loss in 1H 2022)

Aceso Life Science Group Limited Consolidated Earnings Guidance for the Six Months Ended 30 September 2022

Aceso Life Science Group Limited to Report First Half, 2023 Results on Nov 29, 2022

Aceso Life Science Group Limited (SEHK:474) agreed to acquire 4% stake in Quanzhou Donghai Bay Asset Management Company Limited for approximately CNY180 million.

Aceso Life Science Group Limited Announces Change of Company Secretary

Full year 2022 earnings released: HK$0.051 loss per share (vs HK$0.057 loss in FY 2021)

Aceso Life Science Group Limited, Annual General Meeting, Sep 16, 2022

Full year 2022 earnings released

Aceso Life Science Group Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Aceso Life Science Group Limited Provides Unaudited Consolidated Earnings Guidance for the Year Ended 31 March 2022

Senior Consultant recently bought HK$18m worth of stock

Senior Consultant recently bought HK$4.6m worth of stock

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Non-Executive Director Yao Li has left the company

Full year 2021 earnings released: HK$0.057 loss per share (vs HK$0.049 loss in FY 2020)

Is Aceso Life Science Group Limited (HKG:474) Popular Amongst Insiders?

Have Insiders Sold Aceso Life Science Group Limited (HKG:474) Shares Recently?

Senior Consultant recently sold HK$5.0m worth of stock

First half 2021 earnings released: HK$0.07 loss per share

New 90-day low: HK$0.23

New 90-day low: HK$0.24

First half 2021 earnings released: HK$0.07 loss per share

Aceso Life Science Group Limited to Report First Half, 2021 Results on Nov 25, 2020

New 90-day low: HK$0.28

Senior Consultant recently bought HK$852k worth of stock

Hao Tian Development Group Limited has completed a Follow-on Equity Offering in the amount of HKD 150 million.

Senior Consultant recently bought HK$2.8m worth of stock

New 90-day high - HK$0.34

Full year earnings released - HK$0.049 loss per share

Hao Tian Development Group Limited to Report Fiscal Year 2020 Results on Jun 29, 2020

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기